Asghar Sharifi,Mohsen Azizi,Parastoo Moradi-Choghakabodi,Shapour Aghaei,Arsalan Azizia.In vivo investigation of antimicrobial effects of cinnamaldehyde using immunosuppressed ICR mice with invasive pulmonary aspergillosis[J].Chinese Herbal Medicines (CHM),2019,11(4):429-433
雷公藤多苷联合缬沙坦治疗糖尿病肾病的系统回顾和荟萃分析
In vivo investigation of antimicrobial effects of cinnamaldehyde using immunosuppressed ICR mice with invasive pulmonary aspergillosis
  
DOI:10.1016/j.chmed.2019.09.004
中文关键词:  糖尿病肾病  荟萃分析  雷公藤多苷  缬沙坦
英文关键词:anti-Helicobacter pylori activity  Quercus brantii var. persica  testa extracts
基金项目:
Author NameAffiliation
Asghar Sharifi a Department of Microbiology, Yasuj University of Medical Sciences Medicinal Drug Plant, Medical Microbiology, Yasuj 7591741417, Iran 
Mohsen Azizi a Department of Microbiology, Yasuj University of Medical Sciences Medicinal Drug Plant, Medical Microbiology, Yasuj 7591741417, Iran 
Parastoo Moradi-Choghakabodi b Research Center for Thalassemia and Hemoglobinopathy, Health Research Institute, Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz 61357_15794, Iran 
Shapour Aghaei a Department of Microbiology, Yasuj University of Medical Sciences Medicinal Drug Plant, Medical Microbiology, Yasuj 7591741417, Iran 
Arsalan Azizia a Department of Microbiology, Yasuj University of Medical Sciences Medicinal Drug Plant, Medical Microbiology, Yasuj 7591741417, Iran 
Hits: 130
Download times: 0
中文摘要:
      目的:评价雷公藤多苷联合缬沙坦治疗糖尿病肾病(DN)的疗效和安全性。 方法:本文对12个电子数据库进行综合研究。被纳入的研究分别由两位作者独立使用Review Manager(版本5.2)和Stata(版本12.0)进行提取和分析。 结果:共纳入12项随机对照试验,涉及829例患者。结果表明,联合用药能显著提高DN患者的总有效率(RR = 1.35, 95%CI [1.22, 1.50], P < 0.001)及血清白蛋白水平(平均差(MD) = 3.87, 95%CI [3.12, 4.62], P < 0.001),并显著降低24小时尿蛋白水平 (MD = 0.97, 95%CI [1.19, 0.76], P < 0.001)、尿白蛋白排泄率 (MD = 145.53, 95%CI [227.95, 63.11], P < 0.001)及尿β2微球蛋白水平 (MD = 11.86, 95%CI [13.02, 10.69], P < 0.001)。血清肌酐 (MD = 0.26, 95%CI [7.52, 7.00], P > 0.05),血尿素氮 (MD = 0.25, 95%CI [0.23, 0.74], P > 0.05) 和内源性肌酐清除率 (MD = 0.43, 95%CI [3.48, 2.62], P > 0.05) 无显著性差异。雷公藤多苷联合缬沙坦组不良反应发生率明显高于缬沙坦单药治疗组 (MD=3.41, 95%CI [1.34, 8.66], P < 0.05)。所纳入的所有监测指标均不存在发表偏倚。 结论:雷公藤多苷联合缬沙坦治疗DN疗效确切。然而,联合治疗的安全性有待进一步证实。
英文摘要:
      Objective: Growing problem of antibiotic resistance in Helicobacter pylori, as a common cause of chronic gastritis and even stomach cancer, demands searching for novel candidates of herbal sources. This study is aimed at assessing the antimicrobial activity of aqueous extract obtained from Quercus brantii var. persica seed coat (Testa) on H. pylori isolated from gastric biopsy specimens. Methods: Such specimens were collected from 100 patients presenting with endoscopic gastroduodenal findings. Testa extracts were prepared from Persian Oak forests in the province of Kohgiluyeh and Boyer-Ahmad, IRAN. H. pylori isolates were obtained by a series of standard bacteriology tests and cell culture, then were confirmed by PCR. The activity of testa extracts towards 25 H. pylori isolates was assessed by well diffusion method, microdilution assay, and a disk diffusion assay in vitro. Results were analyzed statistically by one-way ANOVA analysis. Results: Aqueous extract of testa demonstrated an antimicrobial activity with zone diameters of inhibition ranged from 0 mm to 40 mm. Its inhibitory activity increased simultaneously with increasing extract concentration. The lowest MIC and MBC were both recorded as 2 μg/mL. Anti-H. pylori activity of testa extract was approximately close to tetracycline and metronidazole and less than amoxicillin. A potent extract of testa possessed significant inhibitory activity (P < 0.05). Conclusion: Testa extract is suggested as a natural therapeutic source against the gastric H. pylori infection. However, evaluating the in vivo activity of this extract is necessary too.
HTML  View Full Text  View/Add Comment  Download reader
Close
Total Numbers of Visitors 1693362
CopyRight: Tianjin Press of Chinese Herbal Medicines
Address:308# An-shan West Road,Nankai District,Tianjin 300193,China
Tel:+86-22-23006901 Fax::+86-22-23006821 E_mail:chm@tiprpress.com
津备案:津ICP备13000267号 互联网药品信息服务资格证书编号:(津)-非经营性-2015-0031